Skip to Content
MilliporeSigma
All Photos(1)

Documents

B9647

Sigma-Aldrich

(E)-5-(2-Bromovinyl)-2′-deoxyuridine

Synonym(s):

BVdU

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H13BrN2O5
CAS Number:
69304-47-8
Molecular Weight:
333.14
MDL number:
MFCD00058585
UNSPSC Code:
12352200
PubChem Substance ID:
24278280
NACRES:
NA.77

form

powder

Quality Level

200

storage temp.

2-8°C

SMILES string

O=C(C(/C=C/Br)=CN1[C@H]2C[C@H](O)[C@@H](CO)O2)NC1=O

InChI

1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1

InChI key

ODZBBRURCPAEIQ-PIXDULNESA-N

Gene Information

human ... HV1S(3365)

Application

(E)-5-(2-Bromovinyl)-2′-deoxyuridine (BVdU) has been used:
  • as a substrate for thymidine kinase 1 to study its effects on cancer cells by a dual-promoter integrator approach
  • as a bromovinyl nucleoside analog to study its effects on varicella-zoster virus replication in a mouse model
  • as a nucleoside analog prodrug to study its effects on transduced cells

Biochem/physiol Actions

(E)-5-(2-Bromovinyl)-2′-deoxyuridine(BVdU) is a thymidine analog and a well-known inhibitor of Herpes simplex virus type 1 (HSV-1) and Varicella zoster virus (VZV) infections. It shows a minimal effect on HSV-2. BVdU shows therapeutic effects against herpetic keratitis, recurrent herpes labialis, and herpes zoster. BVdU undergoes phosphorylation at its 5’-diphosphate and further to 5’-triphosphate by the virus-encoded thymidine kinase, this results in BVdU acting as a competitive inhibitor to the viral DNA polymerase.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vineet Kumar et al.
Bioorganic & medicinal chemistry letters, 18(20), 5640-5642 (2008-09-18)
Nucleoside-based antiviral drugs have been synthesized using imidazolium-based ionic liquids as reaction medium. The ionic liquids were proved to be better solvents for all the nucleoside in terms of solubility and reaction medium as compared to conventional molecular solvents.
Leonardo D'Aiuto et al.
Schizophrenia bulletin, 41(1), 123-132 (2014-03-14)
Herpes simplex virus, type 1 (HSV-1) commonly produces lytic mucosal lesions. It invariably initiates latent infection in sensory ganglia enabling persistent, lifelong infection. Acute HSV-1 encephalitis is rare and definitive evidence of latent infection in the brain is lacking. However
Lior Nissim et al.
Molecular systems biology, 6, 444-444 (2010-12-24)
Precise discrimination between similar cellular states is essential for autonomous decision-making scenarios, such as in vivo targeting of diseased cells. Discrimination could be achieved by delivering an effector gene expressed under a highly active context-specific promoter. Yet, a single-promoter approach
Tomoyuki Shiota et al.
Antiviral research, 91(2), 142-149 (2011-06-15)
Antiviral-resistant herpesvirus infection has become a great concern for immunocompromised patients. Herpes simplex virus type 1 (HSV-1) infections are treated with viral thymidine kinase (vTK)-associated drugs such as acyclovir (ACV), and most ACV-resistance (ACV(r)) is due to mutations in the
(E)-5-(2-Bromovinyl)-2'-Deoxyuridine (BVDU)
Clercq E, et al.
Medical Research Engineering, 25(1), 1-20 (2005)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service